S&P 500   5,137.13 (+0.80%)
DOW   39,077.86 (+0.21%)
QQQ   445.80 (+1.55%)
AAPL   179.80 (-0.53%)
MSFT   414.74 (+0.27%)
META   501.85 (+2.39%)
GOOGL   138.13 (-0.24%)
AMZN   178.43 (+0.94%)
TSLA   202.93 (+0.52%)
NVDA   821.00 (+3.78%)
NIO   5.82 (+1.22%)
AMD   201.60 (+4.71%)
BABA   74.71 (+0.92%)
T   16.98 (+0.30%)
F   12.42 (-0.16%)
MU   95.72 (+5.64%)
CGC   3.21 (-2.43%)
GE   159.02 (+1.36%)
DIS   111.85 (+0.24%)
AMC   4.39 (+1.62%)
PFE   26.61 (+0.19%)
PYPL   60.66 (+0.53%)
XOM   105.75 (+1.18%)
S&P 500   5,137.13 (+0.80%)
DOW   39,077.86 (+0.21%)
QQQ   445.80 (+1.55%)
AAPL   179.80 (-0.53%)
MSFT   414.74 (+0.27%)
META   501.85 (+2.39%)
GOOGL   138.13 (-0.24%)
AMZN   178.43 (+0.94%)
TSLA   202.93 (+0.52%)
NVDA   821.00 (+3.78%)
NIO   5.82 (+1.22%)
AMD   201.60 (+4.71%)
BABA   74.71 (+0.92%)
T   16.98 (+0.30%)
F   12.42 (-0.16%)
MU   95.72 (+5.64%)
CGC   3.21 (-2.43%)
GE   159.02 (+1.36%)
DIS   111.85 (+0.24%)
AMC   4.39 (+1.62%)
PFE   26.61 (+0.19%)
PYPL   60.66 (+0.53%)
XOM   105.75 (+1.18%)
S&P 500   5,137.13 (+0.80%)
DOW   39,077.86 (+0.21%)
QQQ   445.80 (+1.55%)
AAPL   179.80 (-0.53%)
MSFT   414.74 (+0.27%)
META   501.85 (+2.39%)
GOOGL   138.13 (-0.24%)
AMZN   178.43 (+0.94%)
TSLA   202.93 (+0.52%)
NVDA   821.00 (+3.78%)
NIO   5.82 (+1.22%)
AMD   201.60 (+4.71%)
BABA   74.71 (+0.92%)
T   16.98 (+0.30%)
F   12.42 (-0.16%)
MU   95.72 (+5.64%)
CGC   3.21 (-2.43%)
GE   159.02 (+1.36%)
DIS   111.85 (+0.24%)
AMC   4.39 (+1.62%)
PFE   26.61 (+0.19%)
PYPL   60.66 (+0.53%)
XOM   105.75 (+1.18%)
S&P 500   5,137.13 (+0.80%)
DOW   39,077.86 (+0.21%)
QQQ   445.80 (+1.55%)
AAPL   179.80 (-0.53%)
MSFT   414.74 (+0.27%)
META   501.85 (+2.39%)
GOOGL   138.13 (-0.24%)
AMZN   178.43 (+0.94%)
TSLA   202.93 (+0.52%)
NVDA   821.00 (+3.78%)
NIO   5.82 (+1.22%)
AMD   201.60 (+4.71%)
BABA   74.71 (+0.92%)
T   16.98 (+0.30%)
F   12.42 (-0.16%)
MU   95.72 (+5.64%)
CGC   3.21 (-2.43%)
GE   159.02 (+1.36%)
DIS   111.85 (+0.24%)
AMC   4.39 (+1.62%)
PFE   26.61 (+0.19%)
PYPL   60.66 (+0.53%)
XOM   105.75 (+1.18%)
NASDAQ:ALVR

AlloVir (ALVR) Stock Price, News & Analysis

$0.75
+0.01 (+1.89%)
(As of 02:40 PM ET)
Today's Range
$0.74
$0.76
50-Day Range
$0.64
$0.77
52-Week Range
$0.62
$6.28
Volume
223,937 shs
Average Volume
1.75 million shs
Market Capitalization
$86.19 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.67

AlloVir MarketRank™ Stock Analysis

Analyst Rating
Reduce
1.83 Rating Score
Upside/​Downside
2,376.3% Upside
$18.67 Price Target
Short Interest
Healthy
4.81% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.06mentions of AlloVir in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$69,465 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.75) to ($0.69) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.48 out of 5 stars

Medical Sector

316th out of 957 stocks

Biological Products, Except Diagnostic Industry

47th out of 160 stocks


ALVR stock logo

About AlloVir Stock (NASDAQ:ALVR)

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

ALVR Stock Price History

ALVR Stock News Headlines

Rare Earth Elements: The Workhorse of The Tech Revolution
They're the most underrated yet crucial elements of technology. From renewable energy to military defense, Rare Earths are essential pieces of modern technology. Global superpowers and savvy investors are quickly learning just how valuable they truly are.
AlloVir Investor Deadline Approaching
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
AlloVir Ongoing Deadline Alert
AlloVir Shareholder Action Reminder
See More Headlines
Receive ALVR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AlloVir and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/05/2021
Today
3/01/2024
Next Earnings (Estimated)
3/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ALVR
Fax
N/A
Employees
114
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$18.67
High Stock Price Target
$20.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+2,376.3%
Consensus Rating
Reduce
Rating Score (0-4)
1.83
Research Coverage
6 Analysts

Profitability

Net Income
$-168,710,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.41 per share

Miscellaneous

Free Float
68,940,000
Market Cap
$86.57 million
Optionable
Optionable
Beta
0.84
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives















ALVR Stock Analysis - Frequently Asked Questions

Should I buy or sell AlloVir stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AlloVir in the last year. There are currently 2 sell ratings, 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" ALVR shares.
View ALVR analyst ratings
or view top-rated stocks.

What is AlloVir's stock price target for 2024?

6 Wall Street research analysts have issued 1 year target prices for AlloVir's stock. Their ALVR share price targets range from $17.00 to $20.00. On average, they anticipate the company's share price to reach $18.67 in the next twelve months. This suggests a possible upside of 2,376.3% from the stock's current price.
View analysts price targets for ALVR
or view top-rated stocks among Wall Street analysts.

How have ALVR shares performed in 2024?

AlloVir's stock was trading at $0.6798 at the beginning of the year. Since then, ALVR shares have increased by 10.9% and is now trading at $0.7538.
View the best growth stocks for 2024 here
.

Are investors shorting AlloVir?

AlloVir saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 5,520,000 shares, an increase of 12.2% from the January 31st total of 4,920,000 shares. Based on an average trading volume of 2,140,000 shares, the days-to-cover ratio is currently 2.6 days.
View AlloVir's Short Interest
.

When is AlloVir's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024.
View our ALVR earnings forecast
.

How were AlloVir's earnings last quarter?

AlloVir, Inc. (NASDAQ:ALVR) issued its quarterly earnings data on Thursday, August, 5th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by $0.14.

What other stocks do shareholders of AlloVir own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AlloVir investors own include Advanced Micro Devices (AMD), Cloudera (CLDR), Infinera (INFN), Sonos (SONO), Trevena (TRVN), Abbott Laboratories (ABT), Boeing (BA), Delta Air Lines (DAL), Datadog (DDOG) and FuelCell Energy (FCEL).

When did AlloVir IPO?

(ALVR) raised $252 million in an initial public offering (IPO) on Thursday, July 30th 2020. The company issued 14,800,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, SVB Leerink and Piper Sandler served as the underwriters for the IPO.

Who are AlloVir's major shareholders?

AlloVir's stock is owned by a number of institutional and retail investors. Top institutional investors include Wasatch Advisors LP (3.32%), Vanguard Group Inc. (2.58%), Charles Schwab Investment Management Inc. (0.42%), Goldman Sachs Group Inc. (0.41%), Goldman Sachs Group Inc. (0.41%) and Northern Trust Corp (0.38%). Insiders that own company stock include Agustin Melian, Ann M Leen, Beek Jeroen B Van, Beek Jeroen B Van, Brett R Hagen, David Hallal, Diana Brainard, Edward Miller, Ercem Atillasoy, Gilead Sciences, Inc, Jeffrey S Bornstein, John Robert Wilson, Juan Vera, Morana Jovan-Embiricos and Vikas Sinha.
View institutional ownership trends
.

How do I buy shares of AlloVir?

Shares of ALVR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALVR) was last updated on 3/1/2024 by MarketBeat.com Staff